<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-97108</identifier>
<setSpec>1137-6821</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Fibrinolytic therapy in pulmonary embolism</dc:title>
<dc:description xml:lang="en">There is reasonable evidence that suggests that fibrinolytic therapy accelerates the resolution of PE while simultaneously reducing the recurrence of pulmonary embolism; it can also improve other parameters, such as pulmonary blood flow, lung perfusion, and right ventricular dysfunction. Unfortunately, conclusive evidence demonstrating a mortality reduction is not found in the literature, particularly in those patients who are clinically stable with intermediate to low risk of death. The clinician should assess the mortality risk of the PE relative to both the potential benefits and the adverse effects of fibrinolytic therapy for cardiac arrest and the various risk group presentations. In cardiac arrest related to PE, there are no contraindications to medical fibrinolysis; fibrinolytic therapy likely offers the reasonable chance at survival. In those patients not in cardiac arrest, a categorization into high, intermediate, and low risk groups will aid indecision making. In the absence of significant bleeding risk, those patients who are hemodynamically unstable or have signs of right ventricular dysfunction would likely benefit from fibrinolytic agents &#150; i.e., the high risk group. Intermediate risk presentations demonstrate less benefit such that the consideration of complications not infrequently outweighs fibrinolytic  advantage. The literature is mixed, however, in its recommendations for the intermediate group. And, lastly, the low risk group does not benefit from fibrinolysis. Despite this categorization, the decision to administer a fibrinolytic agent remains challenging; the clinician must consider the risks of PE coupled with the risks of fibrinolysis, as compared with this medication&#146;s potential benefit. The decision to administer a fibrinolytic agent in the setting of PE remains highly individual and is most appropriately addressed by the clinician at the bedside (AU)</dc:description>
<dc:creator>Brady, William J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Existe una evidencia razonable que el tratamiento fibrinolítico acelera la resolución dela embolia pulmonar (EP) mientras que simultáneamente reduce su recurrencia. También puede mejorar otros parámetros, como el flujo sanguíneo pulmonar, la perfusión pulmonar y la disfunción del ventrículo derecho. Desafortunadamente, en la literatura no se ha encontrado evidencia concluyente que demuestre una disminución de la mortalidad, particularmente en aquellos pacientes que están clínicamente estables con riesgo de mortalidad bajo o intermedio. Los clínicos deberían valorar el riesgo de mortalidad de la EP y los potenciales beneficios y efectos adversos del tratamiento fibrinolítico tanto para la parada cardiorrespiratoria como en los distintos grupos de riesgo de presentación. En la parada cardiorrespiratoria secundaria a EP, no existen contraindicaciones para la fibrinolisis médica, que ofrecería una oportunidad razonable de supervivencia. En aquellos pacientes sin parada cardiorrespiratoria, clasificar en grupos de alto, intermedio y bajo riesgo ayudará en la toma de decisiones. En la ausencia de riesgo significativo de sangrado, aquellos pacientes que están hemodinámicamente inestables o tienen signos de disfunción del ventrículo derecho probablemente se beneficiarían de agentes fibrinolíticos &#150;como por ejemplo el grupo de alto riesgo&#150;. Las presentaciones de riesgo intermedio demuestran menor beneficio ya que no es infrecuente que las (..) (AU)</dc:description>
<dc:source>Emergencias (Sant Vicenç dels Horts);23(4): 319-323, ago. 2011. tab</dc:source>
<dc:identifier>ibc-97108</dc:identifier>
<dc:title xml:lang="es">Tratamiento fibrinolítico en la embolia de pulmón</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d6475^s22057</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d12428^s22054</dc:subject>
<dc:subject>^d5478^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12092^s22057</dc:subject>
<dc:subject>^d24892^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201108</dc:date>
</metadata>
</record>
</ibecs-document>
